Abstract SM-1 is a murine monoclonal antibody strongly reactive with a cell membrane antigen of small cell carcinoma (SCC) of the lung but unreactive with the membrane of most other carcinomas and normal tissues including normal bone marrow. We have found that in the presence of human complement, SM-1 antibody is highly cytotoxic to SCC cells. Using three treatments with antibody and complement, more than 99% of SCC cells in culture were lysed, as determined by the chromium release and clonogenic assays. Similar efficiency of SCC cell lysis was observed when one SM-1 antibody treatment was followed by three treatments with human complement. In contrast, there was little antibody-dependent lysis of non-small cell lung cancer cells, other carcinomas, and leukemia cell lines. The amount of chromium released from normal bone marrow cells treated with SM-1 antibody and complement was minimal and was mainly due to the effect of complement alone. Clonogenic assays, including colony-forming unit-granulocytic/monocytic, erythroid burst-forming unit, and colony-forming unit-granulocytic/erythroid/monocytic/megakaryocytic, also showed no significant SM-1 antibody-dependent cytotoxicity on normal bone marrow precursors. Since SM-i antibody is selectively cytotoxic to SCC cells in the presence of human complement, it is a potentially useful agent for the selective eradication of tumor cell contamination in marrows of patients with metastatic small cell lung cancer and possibly for in vivo serotherapy.
Introduction
Small cell carcinoma (SCC)' of the lung displays a high capacity to metastasize to a large number of distant sites, including the adrenals, liver, bone marrow, and brain (1) . In spite of high response rates to chemotherapy and radiation, long-term survivors are rare, mainly due to relapse followed by resistance to chemotherapeutic agents (2) . In an attempt to overcome drug resistance, intensive chemotherapy regimens followed by autologous marrow support have been initiated (3) (4) (5) (6) (7) . Patients who were selected for these regimens presumably had marrows free of tumor cell metastases. However, it has been shown that histological stains are limited in their ability to detect micrometastases of SCC to the bone marrow (8) . In future treatment programs, the prognostic significance of the infusion of bone marrows contaminated with SCC and the possibilities of clearing SCC from the marrow will need to be studied. In this paper, we describe the ability of a murine monoclonal antibody, SM-1, to selectively lyse SCC cells in the presence of human complement. The optimal concentrations of antibody and complement, incubation conditions, and cell target selectivity are examined.
Methods

Cell lines
All the cell lines were grown in Roswell Park Memorial Institute tissue culture medium 1640 (RPMI 1640) with 10% fetal calf serum and I mM glutamine. The SCC cell lines OH I and SW-2 and their reactivity with SM-1 antibody were previously described (9) . Except for the data presented in Table I , experiments with SCC cells were performed using the SW-2 cell line. SLC6 is a human large cell carcinoma line developed in this laboratory. U 1752 is a human squamous carcinoma of lung donated by Dr. J. Bergh, Sweden. T47D is a human breast carcinoma cell line provided by Dr 
Preparation of antibody
The preparation and propagation of the SM-1 hybridoma culture has been previously described (9) . SM-1 cells were injected into Balb/c mice for the production of ascites. Ascitic fluid was centrifuged at 1,500g for 20 min. The clear supernatant was filtered on 0.2-gUm Nalgene filters. The antibody preparations were incubated at 50°C for 20 min to inactivate complement. Aliquots were then frozen and stored at -80°C. Before use in cytotoxicity experiments, the antibodies were diluted with RPMI medium to obtain the appropriate concentration of antibody.
Further purification of antibody from SM-1 supernatant or ascites was performed by affinity chromatography and gel filtration. ProtamineSepharose was prepared by cyanogen bromide coupling of protamine to Sepharose 4B. SM-1 ascites or supernatant was added to the gel and washed with dilute phosphate saline buffer (0.03 M phosphate, 0.025 M NaCI). The washed gel was packed into a chromatography column and washed with dilute phosphate saline buffer to remove proteins other than IgM. The antibody was eluted with 0.08 M phosphate buffer, pH 7.4, with 1 M NaCl. The eluate was concentrated in a dialysis bag covered with Aquacide (Calbiochem-Behring Corp., La Jolla, CA). SM-1 antibody was further purified by passing through a 120-cm Sephacryl 300 column. The major antibody fractions were collected and tested for reactivity with SCC cells. Individual fractions with SCC reactivity were pooled and concentrated.
Cytotoxicity of SM-I antibody and complement toward human SCC Chromium labeling. SCC or marrow cells were labeled with 200 uCi/ ml of 5Cr (New England Nuclear, Boston, MA) for I h at 37°C. The cells were then washed with RPMI 1640 containing I mM of glutamine and 4 mM of Hepes buffer, and incubated in ice for 30 min. After a second wash, the cells were transferred to RPMI medium containing 5% heat-inactivated human serum, 1 mM glutamine, and 4 mM Hepes. The cell concentration was 2 X 106 cells/ml.
Retreatment with antibody and complement. SM-1 antibody was diluted with RPMI medium containing 5% heat-inactivated human serum, I mM glutamine, and 4 mM Hepes. The antibody was added to the test cells and incubation was performed at 370C for 30 min.
Human complement was then added to the wells and incubation was continued at 370C for an additional 30 min. For multiple antibody treatments, the cells were washed with RPMI medium containing 1 mM glutamine, 4 mM Hepes, and heat-inactivated human serum between each treatment. After the final treatment, the cells were washed four times with RPMI medium. The amount of chromium associated with the cell pellet was determined in a gamma counter. The amounts of chromium released from the washes from the antibody treatment were determined and found to be consistent with the chromium remaining associated with the pellet. The chromium counts retained in the cells was then used in the calculation of cell lysis. Colony-forming assays for colony-forming unit (CFU)-granulocytic/ monocytic CFU-granulocytic/erythroid/monocytic/megakarocytic (GEMM) and erythroid burst-forming unit (BFU)-E were performed as previously described by one of the co-authors, Dr. J. D. Griffin (10 Whereas a single exposure to antibody followed by 90 min of complement (Ab + C90) resulted in 60% lysis, two treatments with antibody each followed by 45-min treatments with complement (Ab + C45, Ab + C45) resulted in 71% lysis (Fig. 1) . A further improvement in lysis (>95%) was produced by three treatments with antibody followed by 30-min complement exposure: 3 X (Ab + C30). Reducing the complement exposure time from 30 to 15 min, 3 X (Ab + CI5), reduced SCC lysis to 77%.
The other experiments described below on the optimum dilutions of antibody and complement and the temperature dependence, were performed using three treatments with antibody followed by 30-min incubations with complement. We have since found, however, that the treatment schedule could be simplified further. Instead of repeating the antibody treatments, we examined the effect of a single 30-min preincubation with SM-1 antibody followed by replenishment with complement. As shown in Antibody concentration. The effect of antibody concentration on cell lysis in the presence of a complement dilution of 1:10 is shown in Fig. 3 . Using the three treatments, 3 X (Ab + C), SCC lysis remained at 95% or greater at dilutions of antibody from 1:50 to 1:1,000. A significant decline in efficiency of lysis was seen at dilutions of 1:5,000 or greater. Percent lysis was still >70%, even at dilutions of 10,000. In contrast, three treatments with SM-i antibody in the absence of complement resulted in a negligible level of cell lysis (<3%), even at the highest concentrations of SM-1 antibody.
Complement concentration. Using SM-1 antibody dilution of 1: 100, the effect of varying dilutions of human complement was determined (Fig. 4) . The highest dilution of human complement that gave high levels of synergism with SM-1 antibody was 1: 10, resulting in 99% SCC lysis. Higher dilutions of complement resulted in a rapid decline in the efficiency of cell lysis. For Temperature dependence. Using SM-I antibody at 1:100 dilution and preadsorbed human complement, the optimal temperature for lytic activity was determined. As shown in Fig. 5 , the highest lytic activity, greater than 99% was obtained at 370C. Lower temperatures of incubation resulted in much lower lytic activity. Thus only 65% of the cells were lysed at 40C in otherwise optimal concentrations of antibody and complement for SCC cell lysis.
Cytotoxicity on cancer cell lines and normal cells. CFU-GEMM 7 6 Results (8) . In this paper, we describe the selective toxicity of SM-1 antibody towards SCC cells in the presence of human complement.
The use of human complement was emphasized in these studies for several reasons. Human serum is readily available in large amounts and at low cost as a by-product in the preparation of packed erythrocytes in hospital blood banks. This is particularly important if large volumes of complement are needed for clinical application. If antitumor antibodies are to be used for eradication of metastatic tumor in human marrows in the presence of complement, the use of human complement (perhaps from the patient's own serum) may avoid allergic reactions from reinfusion of heterologous proteins.
We have also found that human complement produces lower levels of nonspecific, antibody-independent lysis of normal bone marrow cells than rabbit complement. The potential for in vivo serotherapy with monoclonal antibodies ( SM-l antibody has potential usefulness, therefore, in the eradication of SCC cells from contaminated marrows. We have also described other monoclonal antibodies with selective toxicity for SCC of the lung (13) . The combined use of these antibodies may allow highly efficient killing of SCC. However, the clinical advantage of antibody treatment of bone marrows before autologous bone marrow transplantation of SCC patients still needs to be evaluated. We have found in a previous study that the use of SM-I antibody allows detection of SCC metastasis in a high proportion of bone marrow specimens from SCC patients, which could not be detected by conventional histological stains, such as Wright-Giemsa stains of bone marrow aspirates and hematoxylin-eosin stains of bone marrow biopsies (8) . A prospective study to evaluate the prognostic significance of this marrow contamination among SCC patients undergoing autologous bone marrow transplantation has been initiated in this institution.
In future programs, we will then be able to evaluate the importance of the use of antibodies, such as SM-1, in clearing SCC metastasis to the bone marrow. In addition, animal studies are in progress to determine the usefulness of SM-I antibody in serotherapy of SCC tumor in vivo.
